Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Near term, Gilead’s Milligan doesn’t see “anything really competitive.”
Advertisement

Related Content

ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings
Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings
Gilead’s Darusentan, A Potential Blockbuster, Posts Positive Phase III Data
CVT And Gilead Look To Lock Out Astellas With Planned Merger
Gilead Positioned To Benefit From Potential HIV Guidelines Change

Topics

Advertisement
UsernamePublicRestriction

Register

PS069319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel